MeiraGTx Holdings plc - Ordinary Shares (MGTX) News
Filter MGTX News Items
MGTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MGTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MGTX News From Around the Web
Below are the latest news stories about MEIRAGTX HOLDINGS PLC that investors may wish to consider to help them evaluate MGTX as an investment opportunity.
High Growth Tech Stocks in the United StatesOver the last 7 days, the United States market has dropped 2.6%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of fluctuating performance and anticipated growth, identifying high growth tech stocks involves looking at companies with innovative technologies and strong potential for future expansion. |
MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now?We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where MeiraGTx Holdings plc (NASDAQ:MGTX) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […] |
Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five yearsMeiraGTx Holdings plc ( NASDAQ:MGTX ) shareholders will doubtless be very grateful to see the share price up 47% in the... |
MeiraGTx granted RMAT designation by U.S. FDA to AAV2-hAQP1MeiraGTx (MGTX) announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation to AAV2-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia, RIX. “This RMAT designation underscores the strength of our data indicating the potential of our AAV2-hAQP1 therapy to significantly improve the lives of patients who suffer from xerostomia following radiation treatment. The requirements for receiving an RMAT designation include |
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinic |
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. |
MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To KnowShareholders might have noticed that MeiraGTx Holdings plc ( NASDAQ:MGTX ) filed its quarterly result this time last... |
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue EstimatesMeiraGTx (MGTX) delivered earnings and revenue surprises of -14.89% and 4,264%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business UpdatesReceived 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies including AAV-AIPL1 Agreed on pathway with MHRA for Marketing Authorization Application (MAA) under exceptional circumstances for AAV-AIPL1 for the treatment of Leber congenital amaurosis (LCA4) retinal dystrophy without further clinical studies Announced positive data from randomized, sham-controlled clinical bridging study of AAV-GAD for the treatment of |
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual CongressMultiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress, which is being held from October 22-25, 2024, in Rome, Italy. The posters are available on the Posters and |